

# Working Through the Paradox of Methotrexate Toxicity



Rais Vohra, MD; Stacy Sawtelle Vohra, MD; Andrew Grock, MD; Jessica Mason, MD\*

\*Corresponding Author. E-mail: [jessicadmason12@gmail.com](mailto:jessicadmason12@gmail.com).

0196-0644/\$-see front matter

Copyright © 2018 by the American College of Emergency Physicians.

<https://doi.org/10.1016/j.annemergmed.2018.06.011>



## SEE RELATED ARTICLE, P. 128.

[Ann Emerg Med. 2018;72:129-132.]

**Editor's Note:** *Annals* has partnered with EM:RAP, enabling our readers without subscriptions to EM:RAP to enjoy their commentary on *Annals* publications. This article did not undergo peer review and may not reflect the view and opinions of the editorial board of *Annals of Emergency Medicine*. There are no financial relationships or other consideration between *Annals* and EM:RAP, or its authors.

## ANNALS CASE

A 65-year-old woman presents with a diffuse necrotic rash, mucositis, and pancytopenia, which blooms into a neutropenic fever and lands her in the hospital for almost 2 weeks.<sup>1</sup> The cause of her syndrome may appear to be an autoimmune process, but in fact it's a complication of the very medication that was prescribed for her rheumatoid arthritis: methotrexate (MTX).

## INTRODUCTION: MTX=WTF

Although it won't be the most common "meth" toxicity that you manage in your emergency department (ED), MTX-related complaints are common, affecting 16% of patients who receive it for rheumatoid arthritis.<sup>2</sup> Although single acute overdoses of MTX are well tolerated,<sup>3-5</sup> long-term overdoses, or accidental misadventures because of dosing errors, are frequent. It is these exposures that commonly cause severe toxicity,<sup>6-8</sup> as illustrated in the case above.

MTX seems to fit perfectly the paradox of clinical medicine: every problem has a solution, but every solution comes with its own set of problems. More specifically, the same pharmacologic properties make MTX both very useful and also quite dangerous. It is beneficial in a broad variety of illnesses, and yet it can damage almost any organ in the body when things run afoul. To cloud things a bit more, MTX toxicity in one patient presentation may not at all resemble that in the next, and toxicity with long-term

dosing can be unpredictable even under the best circumstances.<sup>9</sup> Recognizing the many varieties of MTX-related complications is vital for the emergency physician because early interventions can help mitigate the severity of later complications.

## BACKGROUND: MTX=ADR

To begin with, the dosing of MTX sets the stage for a lot of different adverse drug reactions. In the oncology setting, high-dose MTX protocols use potentially fatal infusions of the drug for its antitumor effects, followed by "rescue" therapy with the antidote to save the patient's own tissues before these take a hit.<sup>10</sup> For central nervous system malignancies, they also use intrathecal MTX, in which overdosing errors can be catastrophic, as suggested by the very reassuring advice to do "cerebrospinal fluid exchange" if something untoward should occur.<sup>11</sup>

You probably won't see high-dose MTX or intrathecal MTX patients in your ED. More commonly, it is the subacute or long-term low oral dosing that gets people into trouble, and these are the complications that present to the ED.<sup>9</sup> MTX is frequently prescribed to be taken at low oral doses for anti-inflammatory effects in autoimmune diseases, which is fine and well, except that patients are told to take it weekly rather than daily.<sup>12,13</sup> However, many people inadvertently take it once a day instead, which leads to rapid drug buildup and subsequent toxicity. Even when taken as prescribed, adverse drug reactions can still occur, particularly if there is any decrease in renal function, as occurs with dehydration or concurrent nephrotoxic drugs.<sup>14</sup>

## PHARMACOLOGY: MTX=FRENEMY

MTX is an antimetabolite with structural similarity to folate.<sup>15</sup> The mechanism of action centers on inhibition of the enzyme dihydrofolate reductase, which converts folic acid into the active form, folinic acid. Folinic acid (also called leucovorin) is an important precursor for the production of thymidine in DNA synthesis and repair. The upshot: MTX

targets rapidly proliferating cells, for better or worse; a subset of cancers, autoimmune diseases, and ectopic pregnancies can be treated by putting the kibosh on DNA manufacture. However, toxicity from MTX is related to the same mechanism, causing the most damage to rapidly dividing cells in the bone marrow, skin, mucosal membranes, and gastrointestinal tract.<sup>16-21</sup> MTX toxicity related to drug-drug interactions (such as levetiracetam, trimethoprim-sulfamethoxazole, or proton-pump inhibitors, to name a few) and patient factors can be unpredictable in many cases, and patients receiving this medication can develop toxicity even if receiving it as prescribed.<sup>9,22-25</sup>

### CLINICAL PRESENTATION: MTX=MOF

A patient receiving MTX typically has some serious medical history, so you will likely have a broad differential diagnosis for whatever ails him or her at present. Remember to keep MTX (or other immunomodulating medications) toxicity on your differential, especially if multiple organ failure or a number of unrelated complaints and laboratory results begin to materialize during the evaluation.

Think of MTX in any patient with cancer, rheumatoid arthritis, psoriasis, or recent ectopic pregnancy who presents with multiple organ failure. Toxicity develops in organs with the most rapid cell turnover first, causing dermatitis, stomatitis, mucositis, gastrointestinal bleeding, diarrhea, anemia, neutropenia, or straight-up pancytopenia. Secondary effects include neutropenic fever, ischemia, hemorrhage, electrolyte and fluid losses, hepatotoxicity, and pulmonary toxicity.<sup>26,27</sup> Renal injury either as a complication or precipitating cause of MTX building up<sup>10</sup> is noteworthy because MTX and its metabolites can precipitate in the renal tubules under acidic conditions, leading to acute tubular necrosis.<sup>14</sup>

MTX levels can be obtained in some centers, but for most this will likely be a send-out laboratory test, rendering it less valuable in the ED.<sup>28</sup> Fortunately, you can make a fairly accurate assessment by using excellent history-taking and physical examination skills to estimate the patient's risk. This will permit you to start treatment empirically. Furthermore, the initial interventions to treat MTX toxicity are relatively straightforward, safe, and accessible in almost all hospitals.

### TREATMENT: MTX=KFC

There are 3 key strategies to treating MTX toxicity: enhance renal elimination by giving intravenous fluids and alkalinizing the urine, bypass the blocked dihydrofolate reductase enzyme to restart the DNA synthesis process by giving folinic acid (leucovorin), and add glucarpidase to the mix to cleave and inactivate the MTX molecules. Or, as we

like to say here in Fresno, MTX=KFC (kidneys, folinic acid, chainsaws).

#### Step 1

The first step in treatment is to get the kidneys back online, starting with fluid hydration and moving soon to urine alkalinization.<sup>10,15,29</sup> Optimize urine output, with the goal of making at least 60 mL/hour. Urinary alkalinization can also enhance elimination because MTX tends to deposit in the renal tubules when the pH is acidic. You can administer sodium bicarbonate by the intravenous route (the usual cocktail is 100 to 150 mEq in a liter of dextrose 5% in water) or orally (1,300 mg every 4 hours) to increase the urine pH to a target of 7.0 or higher.<sup>30</sup> At that pH, MTX solubility, and hence its elimination, is increased 10-fold compared with that with a urine pH of 5.5.<sup>31</sup> Hemodialysis or hemoperfusion can also be considered to replace renal function and remove MTX, especially in patients with persistent renal impairment.<sup>32,33</sup>

#### Step 2

The next important step is to restart the thymidine pipeline and DNA synthesis by restoring the folate-dependent pathways blocked by MTX.<sup>16,34</sup> We do this by providing intravenous folinic acid (aka tetrahydrofolate, citrovorum factor, or leucovorin).<sup>35</sup> Folate itself is not as effective because this unreduced form requires activation by the dihydrofolate reductase enzyme, which has become incapacitated by MTX. Thymidine has also been used to rescue patients out of MTX toxicity, but it is not currently used.<sup>36</sup>

#### Step 3

Approved in 2012, carboxypeptidase G2 (or glucarpidase) is the newest antidote that has been developed for MTX toxicity. It is a recombinant enzyme derived from a strain of pseudomonas, RS-16.<sup>37</sup> Finally, pseudomonas is doing something good! Glucarpidase is a chemical chainsaw; it cleaves MTX and renders it inactive.<sup>38</sup> For the pharmacology nerds, it works synergistically with leucovorin because its mechanism of action is to cleave MTX in the extracellular compartment while the leucovorin continues to function inside the cell. It's new, it's expensive, and it's not stocked at many hospitals, so it has not yet replaced leucovorin as the first-line agent for MTX toxicity. When MTX levels remain elevated despite urinary alkalinization and the administration of leucovorin, glucarpidase can be added to the regimen.<sup>39,40</sup>

Management of many of the other complications observed in MTX toxicity is typically the major goal of inpatient care.<sup>9,10,13,14</sup> For example, treatment with granulocyte-macrophage colony stimulating factor (or

filgrastim) and antibiotics can be initiated in cases with neutropenia and infection.<sup>13,16</sup> Transfusions, electrolyte repletion, and nutritional supplementation may be needed in patients with severe anemia, dehydration, and dermatitis or mucositis. Dialysis may be needed for persistent renal failure. Steroids seem to help with some types of pneumonitis, which does not respond that well to leucovorin by itself.<sup>18</sup>

In summary, patients with severe MTX toxicity are vulnerable to many complications. Presenting complaints are often related to myelosuppression, mucocutaneous damage, or infection. Treatment of toxic complications centers on rehydration, leucovorin therapy, and glucarpidase in severely ill patients or those with persistently high MTX levels. Secondary complications should be rapidly identified and appropriately addressed in the inpatient setting.

Call your friendly neighborhood regional poison control center or clinical toxicologist to help you work through the fine points of antidote timing and dosing once you begin to suspect MTX toxicity as the cause of any number of patient complaints.

---

*Author affiliations:* From the Department of Emergency Medicine, University of California, San Francisco–Fresno, Fresno, CA (R. Vohra, S. S. Vohra, Mason); California Poison Control System, Fresno Madera Division, Valley Children’s Hospital, Madera, CA; and the Division of Emergency Medicine Greater Los Angeles VA Healthcare System and the David Geffen School of Medicine, University of California–Los Angeles, Los Angeles, CA (Grock).

---


## REFERENCES

- Schall C, Cumpston KL, Lenczowski J, et al. Images in emergency medicine: a woman with severe rash. *Ann Emerg Med.* 2018;72:128, 161.
- Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. Methotrexate for treating rheumatoid arthritis. *Cochrane Database Syst Rev.* 2014;(6):CD000957.
- LoVecchio F, Katz K, Watts D, et al. Four-year experience with methotrexate exposures. *J Med Toxicol.* 2008;4:149-150.
- Chan BS, Dawson AH, Buckley NA. What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning? *Clin Toxicol (Phila).* 2017;55:88-96.
- Hays H, Beuhler MC, Spiller HA, et al. Evaluation of toxicity after acute accidental methotrexate ingestions in children under 6 years old: a 16-year multi-center review. *Clin Toxicol (Phila).* 2018;56:120-125.
- Yélamos O, Català A, Vilarrasa E, et al. Acute severe methotrexate toxicity in patients with psoriasis: a case series and discussion. *Dermatology.* 2014;229:306-309.
- Moore TJ, Walsh CS, Cohen MR. Reported medication errors associated with methotrexate. *Am J Health Syst Pharm.* 2004;61:1380-1384.
- Cairns R, Brown JA, Lynch AM, et al. A decade of Australian methotrexate dosing errors. *Med J Aust.* 2016;204:384.
- Borchers A, Keen CL, Cheema GS, et al. The use of methotrexate in rheumatoid arthritis. *Semin Arthritis Rheum.* 2004;34:465-483.
- Howard SC, McCormick J, Pui CH, et al. Preventing and managing toxicities of high-dose methotrexate. *Oncologist.* 2016;21:1471-1482.
- Finkelstein Y, Zevin S, Heyd J, et al. Emergency treatment of life-threatening intrathecal methotrexate overdose. *Neurotoxicology.* 2004;25:407-410.
- Perregaard H, Aronson JK, Dalhoff K, et al. Medication errors detected in non-traditional databases: types of errors in methotrexate dosing as listed in four different Danish registers. *Eur J Clin Pharmacol.* 2015;71:1375-1379.
- Romão VC, Lima A, Bernardes M, et al. Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity? *Immunol Res.* 2014;60:289-310.
- Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. *Oncologist.* 2006;11:694-703.
- Bertino JR. The mechanism of action of the folate antagonists in man. *Cancer Res.* 1963;23:1286-1306.
- Kivity S, Zafirir Y, Loebstein R, et al. Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients. *Autoimmun Rev.* 2014;13:1109-1113.
- Yang CH, Yang LJ, Jaing TH, et al. Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole. *Int J Dermatol.* 2000;39:621-623.
- Hilliquin P, Renoux M, Perrot S, et al. Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. *Br J Rheumatol.* 1996;35:441-445.
- Rampon G, Henkin C, Jorge VM, et al. Methotrexate-induced mucositis with extra-mucosal involvement after accidental overdose. *An Bras Dermatol.* 2018;93:155-156.
- Deeming GM, Collingwood J, Pemberton MN. Methotrexate and oral ulceration. *Br Dent J.* 2005;198:83-85.
- Troeltzsch M, von Blohn G, Kriegelstein S, et al. Oral mucositis in patients receiving low-dose methotrexate therapy for rheumatoid arthritis: report of 2 cases and literature review. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2013;115:e28-33.
- Luu B, Rodway GW. Does low-dose methotrexate deserve more respect from clinicians? *JAAPA.* 2017;30:12-15.
- Santucci R, Levêque D, Kemmel V, et al. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. *Anticancer Res.* 2010;30:963-965.
- Groenendal H, Rampen FH. Methotrexate and trimethoprim-sulphamethoxazole—a potentially hazardous combination. *Clin Exp Dermatol.* 1990;15:358-360.
- Reeves D, DiDominick S, Finn S, et al. Methotrexate elimination when coadministered with levetiracetam. *Ann Pharmacother.* 2016;50:1016-1022.
- Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. *Ann Rheum Dis.* 2009;68:1100-1104.
- Salaffi F, Manganelli P, Carotti M, et al. Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. *Clin Rheumatol.* 1997;16:296-304.
- Stoller RG, Hande KR, Jacobs SA, et al. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. *N Engl J Med.* 1977;297:630-634.
- Smith S, Nelson LS. Case files of the New York City Poison Control Center: antidotal strategies for the management of methotrexate toxicity. *J Med Toxicol.* 2008;4:132-140.
- Rouch JA, Burton B, Dabb A, et al. Comparison of enteral and parenteral methods of urine alkalinization in patients receiving high-dose methotrexate. *J Oncol Pharm Pract.* 2017;23:3-9.
- Sand TE, Jacobsen S. Effect of urine pH and flow on renal clearance of methotrexate. *Eur J Clin Pharmacol.* 1981;19:453-456.
- Molina R, Fabian C, Cowley B Jr. Use of charcoal hemoperfusion with sequential hemodialysis to reduce serum methotrexate levels in

- a patient with acute renal insufficiency. *Am J Med.* 1987;82:350-352.
33. Chan WK, Hui WF. Sequential use of hemoperfusion and single-pass albumin dialysis can safely reverse methotrexate nephrotoxicity. *Pediatr Nephrol.* 2016;31:1699-1703.
  34. Bertino JR, Levitt M, McCullough JL, et al. New approaches to chemotherapy with folate antagonists: use of leucovorin "rescue" and enzymic folate depletion. *Ann N Y Acad Sci.* 1971;186:486-495.
  35. Flombaum CD, Meyers PA. High-dose leucovorin as sole therapy for methotrexate toxicity. *J Clin Oncol.* 1999;17:1589-1594.
  36. van den Bongard HJ, Mathijt RA, Boogerd W, et al. Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure. *Cancer Chemother Pharmacol.* 2001;47:537-540.
  37. Sherwood RF, Melton RG, Alwan SM, et al. Purification and properties of carboxypeptidase G2 from *Pseudomonas* sp. strain RS-16. Use of a novel triazine dye affinity method. *Eur J Biochem.* 1985;148:447-453.
  38. Schwartz S, Borner K, Müller K, et al. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. *Oncologist.* 2007;12:1299-1308.
  39. Widemann BC, Balis FM, Kim A, et al. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. *J Clin Oncol.* 2010;28:3979-3986.
  40. Ramsey LB, Balis FM, O'Brien MM, et al. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. *Oncologist.* 2018;23:52-61.

## Images in Emergency Medicine

The *Annals* Web site ([www.annemergmed.com](http://www.annemergmed.com)) contains a collection of hundreds of emergency medicine-related images, complete with brief discussion and diagnosis, in 18 categories. Go to the Images pull-down menu and test your diagnostic skill today. Below is a selection from the Neurology/Neurosurgery Images.



“Long-Term Survival Following Complete Medulla/Cervical Spinal Cord Transection” by Gautschi and Zellweger, April 2007, Volume 49, #1, pp. 540, 545.